Eli Lilly combination therapy 'significantly' reduces COVID-19 hospitalizations and deaths in study

Eli Lilly
(Image credit: AP Photo/Darron Cummings)

Eli Lilly said Wednesday its combination antibody therapy "significantly" reduced COVID-19 deaths and hospitalizations in a phase 3 study.

In a study consisting of more than 750 high-risk patients with COVID-19, the company said a combination of bamlanivimab and etesevimab cut the risk of hospitalization and death by 87 percent, Reuters reports.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Brendan Morrow

Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.